Cannabinoid · Pharmaceutical (synthetic analog)
Nabilone is a synthetic analog of THC (a designed molecule, not identical to THC) that is FDA-approved as Cesamet for chemotherapy-induced nausea and vomiting that has failed to respond to standard anti-nausea drugs. Being synthetic and orally stable makes its dosing predictable.
A designed THC analog
Not the same molecule as THC
Unlike dronabinol (which is THC), nabilone is a structurally distinct synthetic that acts at the same CB1 receptor. It is reserved for chemotherapy nausea unresponsive to conventional treatment, and is also used off-label in some pain and spasticity settings.
Clinical Pharmacology and Antiemetic Guideline Evidence
Nabilone (CAS 51022-71-0; C24H36O3) is a synthetic dibenzopyran-9-one analog of Delta-9-THC among synthetic cannabinoids that acts as an orally bioavailable agonist at central CB1 receptors involved in regulating the brainstem emetic reflex (Alderman et al., 2022, Supportive Care in Cancer, PubMed PMID 36525085). Clinical practice guidelines from NICE and oncology supportive-care panels restrict prescription nabilone (Cesamet) to refractory chemotherapy-induced nausea and vomiting (CINV) that has failed conventional 5-HT3 and NK1 receptor antagonist regimens, noting frequent dose-limiting central nervous system adverse effects including drowsiness, dizziness, and orthostatic hypotension (Chang-Douglass et al., 2020, BMJ, PubMed PMID 32317246).
FAQ
Is nabilone the same molecule as natural Delta-9-THC?
No. Nabilone is a synthetic dibenzopyran-9-one analog with a ketone group at the C9 position (unlike dronabinol, which is synthetic Delta-9-THC), giving it distinct oral pharmacokinetics and hepatic metabolism.
What is nabilone (Cesamet) clinically approved to treat?
Nabilone is approved as a prescription capsule for chemotherapy-induced nausea and vomiting (CINV) in patients who have not responded adequately to conventional antiemetic therapies.
Does nabilone produce psychoactive or sedative side effects?
Yes. Because nabilone activates central CB1 receptors, clinical trials report frequent dose-related drowsiness, vertigo, dry mouth, and occasional dysphoria or orthostatic hypotension.
Sources
- Nabilone (Cesamet) FDA prescribing information, DailyMed. dailymed.nlm.nih.gov
Part of the NOIDS cannabinoids index. Educational reference, not medical advice.